Skip to main content
Clinical Trials/NCT04139629
NCT04139629
Unknown
N/A

Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and Efficiency of Treatment With Assisted Reproduction Technologies (ART) in Women With Tubal Factor Infertility

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology1 site in 1 country292 target enrollmentOctober 25, 2019

Overview

Phase
N/A
Intervention
antichlamydial antibody test
Conditions
Antichlamydial Antibodies
Sponsor
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
Enrollment
292
Locations
1
Primary Endpoint
number of oocytes (COCs)
Last Updated
4 years ago

Overview

Brief Summary

In a prospective cohort study investigators will examine characteristics and clinical outcomes of treatment with ART in women with tubal factor infertility (TFI) with regard to seropositivity to antichlamydial antibodies.

Detailed Description

At the first day of stimulation blood analyses for immunoglobulin G (IgG), immunoglobulin A (IgA) and immunoglobulin M (IgM) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study. According to the result of chlamydial antibody test (CAT) participants will be divided into two groups: group A - women with at least one of antibodies detected (CAT+); Group B - seronegative subjects (CAT-). Women of both groups will undergo a conventional ovarian stimulation (COS) with GnRH antagonist and daily gonadotropin administration at the dose of 150-300 international unit (IU). Retrieved oocytes following fertilization (conventional IVF or ICSI) will be cultured to Day 3-5 in vitro; ultrasound guided single or double embryo transfer will be performed; remaining embryos of eligible quality will be vitrified. Patients will be followed up to live birth. Frozen/thawed embryo transfers (FET) will be performed until at least one live birth (≥20 weeks of gestation) occurred or all embryos resulting from the mentioned assisted ovarian stimulation were used.

Registry
clinicaltrials.gov
Start Date
October 25, 2019
End Date
October 30, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
Responsible Party
Principal Investigator
Principal Investigator

Valeria Muller

Doctor at IVF department

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Eligibility Criteria

Inclusion Criteria

  • Tubal factor infertility diagnosed by laparoscopy;
  • Female age between 20-41 years;
  • BMI 17,5-35 kg/m2;
  • Early follicular phase follicle stimulating hormone (FSH) ≤15 IU/L
  • Presence of viable spermatozoa in partner's sperm;
  • Signed informed consent.

Exclusion Criteria

  • previous ovarian surgery;
  • endometriosis;
  • antimullerian hormone (AMH) level ≤0,3 ng/ml;
  • hyper- or hypogonadotropic ovarian failure;
  • severe male factor infertility;
  • Pre-existing medical condition preventing or interfering with IVF treatment: any clinically significant systemic disease; inherited or acquires thrombophilia and thromboembolism; endocrine or metabolic abnormalities; moderate or severe impairment of renal or hepatic function; any oncological diseases in anamnesis; known history of recurrent miscarriage, abnormal karyotype of both partners; currently active pelvic inflammatory disease;
  • Abnormal IVF screening tests: Papanicolaou (PAP) smear, Syphilis, HIV 1\&2, Hepatitis B, Hepatitis C, Chlamydia, and Gonorrhea;
  • Presence of uterine pathology: Asherman's Syndrome, endometrial polyps, nodus form of adenomyosis or uterine fibroids ≥3 mm in diameter;
  • Visualization of ovarian cysts ≥25 mm, endometriomas or hydrosalpinx;
  • One or more follicles ≥8 mm at the start of the COS protocol.

Arms & Interventions

antibody positive (CAT+)

patients found positive for one of the assayed antichlamydial antibodies

Intervention: antichlamydial antibody test

antibody positive (CAT+)

patients found positive for one of the assayed antichlamydial antibodies

Intervention: treatment of infertility with ART

antibody negative (CAT-)

women with negative antichlamydia antibody test

Intervention: antichlamydial antibody test

antibody negative (CAT-)

women with negative antichlamydia antibody test

Intervention: treatment of infertility with ART

Outcomes

Primary Outcomes

number of oocytes (COCs)

Time Frame: 2-4 weeks after after assignment (at oocyte recovery day)

obtained during oocyte pick-up (OPU)

Secondary Outcomes

  • Number/rate of participants with poor or suboptimal response to COS(2-4 weeks after after assignment (at oocyte recovery day))
  • Number / rate of best and good quality embryos per transfer(3-5 weeks after after assignment (at ET day))
  • Implantation rate(3-4 weeks after fresh or frozen/thawed ET)
  • Number of low prognostic patients(up to 1 week after assignment)
  • Duration of stimulation(2-4 weeks after assignment)
  • clinical pregnancy rate(5-6 weeks after starting the stimulation or 3-4 weeks after frozen/thawed ET)
  • Number / rate of mature (MII) oocytes(2-4 weeks after after assignment (at oocyte recovery day))
  • Fertilization rate(at day 1 after oocyte recovery)

Study Sites (1)

Loading locations...

Similar Trials